Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…(MRAs) improve autonomic function in non-diabetic diseases, and finerenone, a non-steroidal MRA, has demonstrated promising results in man…
…cal differences.3 Aim and Objectives To compare the efficacy of finerenone and spironolactone through indirect adjusted comparisons (ICs) …
…arched. All randomised controlled clinical trials investigating Finerenone combined with SGLT2i for DKD treatment will be included. Data e…
…omes and 37% of its improvement in CV outcomes were mediated by finerenone’s effect on decreasing UACR.28 While achieving reduction in UAC…
…tes (SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone and tirzepatide):• Lower risk (three or fewer cardiovascular risk factors witho…
…ncluding effects of SGLT-2 inhibitors, GLP-1RAs, finerenone and tirzepatide.Systematic review registration PROSPERO number: CRD42022325948.…
… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…
…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …
…inuric LN, SGLT2i may be added after disease stabilization, and GLP-1 RA are reserved for those with type 2 diabetes. MRA use is not sta…